New Biomarker Study of Rapid-Acting Treatment for Acute Depression

Apimostinel is in development for the treatment of acute depressive disorders and depression with suicidality.

Anantha Shekhar, MD, PhD, discusses Gate Neuroscience's phase 1 study of rapid-acting antidepressant, apimostinel.

You can read more about apimostinel in "Phase 1 Study of Apimostinel for Depression Doses First Participants."

Dr Shekhar is senior vice chancellor for the health sciences and John and Gertrude Petersen Dean of the School of Medicine at the University of Pittsburgh. He is also a professor of psychiatry and a professor of clinical and translational science, as well as Chief Scientific Officer of Gate Neuroscience.

Related Videos
View All
© 2023 MJH Life Sciences

All rights reserved.